KCT0006311
Not yet recruiting
未知
A phase 1 multiple dose study to evaluate the safety, tolerability and pharmacodynamics of GEN-001 in healthy male volunteers
ConditionsNot Applicable
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not Applicable
- Sponsor
- Jeonbuk National University Hospital
- Enrollment
- 12
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\) A healthy adult who is 19 \~50 years old at the screening test
- •(2\) Body mass index (BMI) greater than 18\.0 kg / m^2 and less than 28\.0 kg / m^2 and body weight greater than 55 kg
- •? Body Mass Index (BMI) \= body weight (kg) / height (m)^2
- •(3\) A person who have no congenital or chronic disease within the last 3 years and have no pathological symptoms or findings as a result of medical examination
- •(4\) A person who has bowel movements of Bristol Stool form scale Type 3\-5 more than 3 times a week
- •(5\) A person who has been judged to be suitable for the test subject to be tested at screening such as laboratory tests (hematology test, blood chemistry test, urine test, etc.) and electrocardiogram test conducted according to the characteristics of medicines
- •(6\) A person who signed the written consent to participate in this study with full understanding of the purpose and contents of the examination prior to taking the test
- •(7\) A persion who has the ability and willingness to participate in the study
Exclusion Criteria
- •(1\) A person with evidence or evidence of clinically significant blood, kidney, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, mental, neurological or allergic disease (except for asymptomatic seasonal allergies at the time of administration)
- •(2\) A person with a history of gastrointestinal disorders (esophageal ataxia or esophageal strictures, Crohn's disease) or surgery (except for simple cecal surgery or hernia surgery) that can affect the absorption of drugs
- •(3\) Patients with a history of hypersensitivity to the drug and additives of probiotics or lactic acid bacteria preparetations or other drug(aspirin, antibiotics, etc) and food containing components
- •(4\) Patients with genetic problems such as galactose intolerance, Lapp lactose dehydrogenase deficiency or glucose\-galactose uptake disorder
- •(5\) Screening If you have a regular alcohol intake history of more than 210 g/week within 6 months (10 g of beer (5%) \= 10 g, 1 glass of soju (20%) \= 8 g , Wine (12%), 1 cup (125 mL) \= 12 g)
- •(6\) Smokers within 3 months of screening
- •(7\) A persion who took other clinical trials or bioequivalence testing drugs within 6 months before the first administration of investigational product
- •(8\) Anyone with a history of major alcohol or drug abuse within a year of screening
- •(9\) A person who is at risk of serious adverse/chronic medical, mental, or laboratory examinations that may increase the risk due to the administration of medicines for clinical trials and participation in testing, or may interfere with the interpretation of test results
- •(10\) A person who is being treated with steroid drugs
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a plasma cell tumor.Multiple myeloma in early relapse after intensive front line therapyMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2018-001741-14-ITOSPEDALE SAN RAFFAELE3
Unknown
Phase 1
A Phase 1, Repeat Dose Study to Evaluate the Safety, Tolerability, Biological Activity, and Pharmacokinetics of ND-L02-s0201 Injection in Japanese Subjects with Advanced Hepatic Fibrosis (METAVIR F3-4)Advanced Hepatic FibrosisJPRN-jRCT2080222907ITTO DENKO CORPORATIO9
Unknown
Phase 1
A Phase 1, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Hormone Therapy-Resistant Prostate Cancer SubjectsProstate cancerJPRN-jRCT2080220970Takeda Pharmaceutical Company Limited
Completed
Phase 1
Clinical trial to evaluate safety, tolerability and pharmacokinetic of herbal (ICB-014-A002) capsule in healthy adult volunteers.CTRI/2018/01/011259Indian Institute of Integrative Medicine Council of Scientific Industrial Research38
Recruiting
Phase 1
Single Dose Study of MK-2214 in Healthy Japanese ParticipantsAlzheimer's DiseaseJPRN-jRCT2031220627Tanaka Yoshiyuki48